KRAS基因突变在胰腺导管腺癌（PDAC）中的高频出现，使其成为研究人员梦寐以求的靶点。然而，这一领域长期以来被视为“不可成药”（undruggable）的难题。随着新技术和新思路的涌现，靶向KRAS的治疗正逐渐成为攻克PDAC的重要突破口。

IND for QTX3544 is third for Quanta within one year – – Initiated combination portion of Phase 1 clinical trial of QTX3046, an oral KRAS G12D-selective dual ON/OFF state allosteric inhibitor ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients ...

Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild ...

KRAS G12C is the most common form of KRAS mutation in lung cancer, while G12D is found more commonly in other diseases like pancreatic and colorectal cancers. Dr Hu Tao, co-founder and chief ...

The criteria for consideration of translational and clinical research in Nature Medicine are originality, timeliness and impact on improving human health by addressing unmet clinical needs.

Jan. 9, 2025 — A research team has carried out the most comprehensive assessment to date of how logging and conversion to oil palm plantations affect tropical ...

Nature Research Intelligence gives you a greater focus on real-world impact, enabling you to find the most effective strategies and collaborations to deliver maximum benefit from your research ...

Clinical validation of this combination has been demonstrated with the approval of adagrasib in KRASG12C-mutated CRC. Additionally, the phase 1 clinical trial evaluating QTX3034, an oral ...

Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the prevention and treatment of disease. Nanomedicine involves the use of nanoscale materials ...